AtaiBeckley Wins OVID Health Silver Award and Secures FDA Priority Review Voucher
AtaiBeckley won the Silver Award in OVID Health’s Patient Participant Index for its 2023 PsyPAN partnership, delivering trial workshops, a white paper and a 12-month UK peer-support pilot funded by a 2025 grant. An April 2026 executive order awarded FDA priority review vouchers to AtaiBeckley, potentially speeding its therapy approvals.
1. Silver Award for Patient Partnership
AtaiBeckley received the Silver Award in OVID Health’s 2026 Patient Participant Index for its collaboration with the Psychedelic Participant Advocacy Network, which began in 2023. This multiyear initiative produced qualitative workshops, the “Participants in Their Own Words” white paper and a 12-month UK peer-support pilot funded by an unrestricted 2025 grant.
2. FDA Priority Review Voucher Secured
Following an April 2026 executive order supporting psychedelic drugs, the FDA granted national priority review vouchers to selected developers including AtaiBeckley. These vouchers could shorten regulatory review by several months, accelerating the path to market for its rapid-acting mental health therapy candidates.